<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SUCCINYLCHOLINE CHLORIDE <img border="0" src="../images/pr.gif"/></span><br/>(suk-sin-ill-koe'leen)<br/><span class="topboxtradename">Anectine, </span><span class="topboxtradename">Quelicin, </span><span class="topboxtradename">Sucostrin<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">depolarizing skeletal muscle relaxant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>20 mg/mL, 50 mg/mL, 100 mg/mL injection; 500 mg, 1 g vials</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic, ultrashort-acting depolarizing neuromuscular blocking agent with high affinity for acetylcholine (ACh) receptor
         sites.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Initial transient contractions and fasciculations are followed by sustained flaccid skeletal muscle paralysis produced by
         state of accommodation that develops in adjacent excitable muscle membranes. Rapidly hydrolyzed by plasma pseudocholinesterase.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To produce skeletal muscle relaxation as adjunct to anesthesia; to facilitate intubation and endoscopy, to increase pulmonary
         compliance in assisted or controlled respiration, and to reduce intensity of muscle contractions in pharmacologically induced
         or electroshock convulsions.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to succinylcholine; family history of malignant hyperthermia. </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>During delivery by cesarean section; lactation; kidney, liver, pulmonary, metabolic, or cardiovascular disorders; dehydration,
         electrolyte imbalance, patients taking digitalis, severe burns or trauma, fractures, spinal cord injuries, degenerative or
         dystrophic neuromuscular diseases, low plasma pseudocholinesterase levels (recessive genetic trait, but often associated with
         severe liver disease, severe anemia, dehydration, marked changes in body temperature, exposure to neurotoxic insecticides,
         certain drugs); collagen diseases, porphyria, intraocular surgery, glaucoma; pregnancy (category C).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Surgical and Anesthetic Procedures</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.31.1 mg/kg administered over 1030 sec, may give additional doses prn <span class="rdroute">IM</span> 2.54 mg/kg up to 150 mg<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 12 mg/kg administered over 1030 sec, may give additional doses prn <span class="rdroute">IM</span> 2.54 mg/kg up to 150 mg<br/><br/><span class="indicationtitle">Prolonged Muscle Relaxation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.510 mg/min by continuous infusion<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give IM injections deeply, preferably high into deltoid muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Use only freshly prepared solutions; succinylcholine hydrolyzes rapidly with consequent loss of potency.</li>
<li>Give initial small test dose (0.1 mg/kg) to determine individual drug sensitivity and recovery time.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">Intermittent/</span><span class="methodtype">Continuous:</span> Dilute 1 g in 5001000 mL of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a bolus dose over 30 sec.  <span class="methodtype">Intermittent/</span><span class="methodtype">Continuous:</span> Preferred. Give at a rate of 0.510 mg/min. Do not exceed 10 mg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Sodium bicarbonate,</b>
<b>thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>
            				Note: Expiration date and storage before and after reconstitution; varies with the manufacturer.
            			
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Muscle fasciculations,</span> profound and prolonged muscle relaxation, muscle pain. <span class="typehead">CV:</span>
<span class="speceff-common">Bradycardia,</span> tachycardia, hypotension, hypertension, arrhythmias, sinus arrest. <span class="typehead">Respiratory:</span>
<span class="speceff-both">Respiratory depression,</span> bronchospasm, hypoxia, <span class="speceff-life">apnea</span>. <span class="typehead">Body as a Whole:</span>
<span class="speceff-life">Malignant hyperthermia</span>, increased IOP, excessive salivation, enlarged salivary glands. <span class="typehead">Metabolic:</span> Myoglobinemia, hyperkalemia. <span class="typehead">GI:</span> Decreased tone and motility of GI tract (large doses). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Aminoglycosides,</b>
<b>colistin,</b>
<b>cyclophosphamide,</b>
<b>cyclopropane,</b>
<b>echothiophate iodide,</b>
<b>halothane,</b>
<b>lidocaine,</b>
<b>
<small>MAGNESIUM SALTS</small>, methotrimeprazine,</b>
<b>
<small>NARCOTIC ANALGESICS,</small>
</b>
<b>
<small>ORGANOPHOSPHAMIDE INSECTICIDES,</small>
</b>
<b>
<small>MAO INHIBITORS,</small>
</b>
<b>
<small>PHENOTHIAZINES,</small>
</b>
<b>procaine,</b>
<b>procainamide,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>propranolol</b> may prolong neuromuscular blockade; <span class="classification">digitalis glycosides</span> may increase risk of cardiac arrhythmias. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 0.51 min IV; 23 min IM. <span class="typehead">Duration:</span> 23 min IV; 1030 min IM. <span class="typehead">Distribution:</span> Crosses placenta in small amounts. <span class="typehead">Metabolism:</span> Metabolized in plasma by pseudocholinesterases. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline serum electrolytes. Electrolyte imbalance (particularly potassium, calcium, magnesium) can potentiate
            effects of neuromuscular blocking agents.
         </li>
<li>Be aware that transient apnea usually occurs at time of maximal drug effect (12 min); spontaneous respiration should
            return in a few seconds or, at most, 3 or 4 min.
         </li>
<li>Have immediately available: Facilities for emergency endotracheal intubation, artificial respiration, and assisted or controlled
            respiration with oxygen.
         </li>
<li>Monitor vital signs and keep airway clear of secretions.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Patient may experience postprocedural muscle stiffness and pain (caused by initial fasciculations following injection) for
            as long as 2430 h.
         </li>
<li>Be aware that hoarseness and sore throat are common even when pharyngeal airway has not been used.</li>
<li>Report residual muscle weakness to physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>